OncoMatch/Clinical Trials/NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Is NCT07066657 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies MRG007 for locally advanced or metastatic solid tumors.
Treatment: MRG007 — This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Gastric Cancer
Pancreatic Cancer
Biomarker criteria
Required: CDH17 any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CDH17-targeting anti-tumor therapy
Received CDH17-targeting anti-tumor therapy
Cannot have received: other investigational product
received other investigational product ... within 4 weeks prior to the first dose
Cannot have received: systemic corticosteroids
received ... systemic corticosteroids ... within 4 weeks prior to the first dose
Cannot have received: major organ surgery
surgery for major organs within 4 weeks prior to the first dose
Cannot have received: anti-tumor therapy
received anti-tumor therapy within 3 weeks or within 5 half-lives prior to the first dose, whichever is shorter
Cannot have received: radiotherapy
received radiotherapy within 2 weeks prior to the first dose
Lab requirements
Blood counts
Organ functions and coagulation function must meet the basic requirements
Kidney function
Organ functions and coagulation function must meet the basic requirements
Liver function
Organ functions and coagulation function must meet the basic requirements
Organ functions and coagulation function must meet the basic requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- ULCA · Los Angeles, California
- UCSF · San Francisco, California
- University of Colorado · Aurora, Colorado
- Sarah Cannon Research Institute · Denver, Colorado
- Sarah Cannon Research Institute · Sarasota, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07066657 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CDH17-targeting anti-tumor therapy, other investigational product, systemic corticosteroids disqualifies patients from enrollment.
Does this trial require CDH17?
Yes, CDH17 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages